2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2001

Methotrexate and Injectable Tumor Necrosis Factor Alpha Inhibitor Adherence and Persistence in Children with Rheumatic Diseases
Abstract Number: 2170

Methotrexate and Interstitial Lung Disease in Rheumatoid Arthritis – A Systematic Literature Review and Meta-Analysis
Abstract Number: 2161

Methotrexate Polyglutamate Concentrations in Erythrocytes Are a Potential Tool for Therapeutic Drug Monitoring of Methotrexate Response in Rheumatoid Arthritis
Abstract Number: 438

Methyl Supplementation of Rheumatoid Arthritis Synovial Fibroblasts Regulates the Expression of Transcription Factors and Matrix Metalloproteinases
Abstract Number: 2346

MHC II-Independent Regulation of Intestinal Tregs
Abstract Number: 1670

Microarray Analysis for miRNA Expression in Juvenile Dermatomyositis (JDM)
Abstract Number: 1629

Microarray Analysis of Acute and Intercritical Gout
Abstract Number: 1002

Microrna Expression Profiles in Peripheral Blood Mononuclear Cells of Early Onset Psoriatic Arthritis
Abstract Number: 881

Microrna-155 Regulates Chemokines and Chemokine Receptors in Rheumatoid Arthritis Monocyte
Abstract Number: 2

Microrna-558 Regulates the Expression of Cyclooxygenase-2 and IL-1beta Responses in Human Articular Chondrocytes
Abstract Number: 1539

Microscopic Polyangiitis: A Large Single Center Series
Abstract Number: 805

Milnacipran Increases Cortical to Brainstem Connectivity During Pain in Fibromyalgia
Abstract Number: 802

Milnacipran Reduces Brain Activity During Pain in Fibromyalgia
Abstract Number: 244

Minimal Clinically Important Difference and Patient Acceptable Symptom State for the Oarsi-Omeract Intermittent and Constant OA Pain (ICOAP) Measure
Abstract Number: 1555

Minimal Clinically Important Difference for Seven Measures of Fatigue in Patients with Systemic Lupus Erythematosus – Results From a Swedish Setting

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].